行情

TARA

TARA

ArTara Therapeutics
NASDAQ

实时行情|Nasdaq Last Sale

24.00
-0.25
-1.03%
已收盘, 16:00 04/02 EDT
开盘
22.84
昨收
24.25
最高
24.00
最低
21.12
成交量
4,507
成交额
--
52周最高
42.49
52周最低
8.80
市值
1.40亿
市盈率(TTM)
-0.0196
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

中性

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测TARA价格均价为1.000,最高价位1.000,最低价为1.000。

EPS

TARA 新闻

更多
  • 瑞幸咖啡公关负责人:瑞幸方面不做任何答复
  • 央视 · 1小时前
  • 受疫情影响 H&M上月销售额暴跌近一半
  • 新浪财经 · 1小时前
  • 京东徐雷谈瑞幸财务造假:对中国企业影晌是破坏性的
  • 新浪科技 · 1小时前
  • 证监会:高度关注瑞幸咖啡事件 对该财务造假行为表示强烈谴责
  • 环球网 · 1小时前

所属板块

生物技术和医学研究
+3.33%
制药与医学研究
+2.80%

热门股票

代码
价格
涨跌幅

TARA 简况

ArTara Therapeutics Inc., formerly Proteon Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases. Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. Its product pipeline includes TARA 002 and IV choline chloride for injection. TARA 002 is its lead program focused on the treatment of Lymphatic Malformations (LMs). TARA 002 is a cellular therapy based on OK-432, also known as Picibanil, which is derived from a genetically distinct strain of Streptococcus Pyogenes. IV choline chloride is an enzyme replacement therapy for patients with choline deficiency who exhibit symptoms of liver impairment. IV Choline Chloride is being developed for the treatment of Intestinal Failure Associated Liver Disease (IFALD).
展开

微牛提供Artara Therapeutics Inc(NASDAQ-TARA)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的TARA股票新闻,以帮助您做出投资决策。